Emergence of HIV-1 Drug Resistance Mutations in Mothers on Treatment
Total Page:16
File Type:pdf, Size:1020Kb
Martin-Odoom et al. Virology Journal (2018) 15:143 https://doi.org/10.1186/s12985-018-1051-2 RESEARCH Open Access Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana Alexander Martin-Odoom1* , Charles Addoquaye Brown1, John Kofi Odoom2, Evelyn Yayra Bonney2, Nana Afia Asante Ntim2, Elena Delgado3, Margaret Lartey4, Kwamena William Sagoe1, Theophilus Adiku1 and William Kwabena Ampofo2 Abstract Background: Antiretrovirals have been available in Ghana since 2003 for HIV-1 positive pregnant women for prevention of mother-to-child transmission (PMTCT). Suboptimal responses to treatment observed post-PMTCT interventions necessitated the need to investigate the profile of viral mutations generated. This study investigated HIV-1 drug resistance profiles in mothers in selected centres in Ghana on treatment with a history of prophylaxis. Methods: Genotypic Drug Resistance Testing for HIV-1 was carried out. Subtyping was done by phylogenetic analysis and Stanford HIV Database programme was used for drug resistance analysis and interpretation. To compare the significance between the different groups and the emergence of drug resistance mutations, p values were used. Results: Participants who had prophylaxis before treatment, those who had treatment without prophylaxis and those yet to initiate PMTCT showed 32% (8), 5% (3) and 15% (4) HIV-1 drug resistance associated mutations respectively. The differences were significant with p value < 0.05. Resistance Associated Mutations (RAMs) were seen in 14 participants (35%) to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The most common NRTI mutation found was M184 V; K103 N and A98G were the most common NNRTI mutations seen. Thymidine Analogue Mutations (TAMs) such as M41 L, K70R and T215Y were found in all the groups; the most common of the TAMs found were M41 L and T215Y. Majority of the subtypes were CRF02_AG (82%). Conclusion: In Ghana initiation of uninterrupted treatment upon diagnosis, coupled with drug resistance testing, would produce a better treatment outcome for HIV-1 positive pregnant women. Keywords: Antiretroviral therapy, Phylogenetic analysis, Drug resistance profiles, Treatment outcome Background emergence of HIV-1 drug resistance viral strains is a major Antiretroviral therapy (ART) was started in Ghana in 2003 obstacle in the effective management of HIV infection and and has gone through a number of revisions to provide AIDS. Drug resistant strains may develop due to exposure appropriate health care and support for HIV positive to drugs but drug naïve persons could also be infected with persons across the whole of Ghana [1]. The National AIDS/ drug-resistant strains [3]. The Ghana HIV Drug Resistance STI Control Programme (NACP) of the Ghana Health (HIVDR) Threshold Survey was initiated in 2007 [4]togen- Service implemented various research-backed interventions erate information on the presence of HIV drug-resistant to monitor drug resistance known to arise in HIV patients strains in the locality where Ghana’sARTforHIVwasfirst through the use of the Antiretrovirals (ARVs) [2]. The introduced. It was also to seek information on active trans- mission of HIV drug-resistant strains in drug-naïve persons in the country so as to signal action to address transmitted * Correspondence: [email protected]; [email protected] 1Department of Medical Laboratory Sciences, School of Biomedical & Allied HIV drug resistance (HIVDR) in Ghana. A Survey of Emer- Health Sciences, College of Health Sciences, University of Ghana, P.O. Box KB gence of HIV Drug Resistance was also initiated by the 143, Korle Bu, Accra, Ghana NACP to monitor the emergence of HIV drug resistance in Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Martin-Odoom et al. Virology Journal (2018) 15:143 Page 2 of 9 Ghana amongst patients initiating antiretroviral therapy until labour onset when a single dose Nevirapine (sd NVP), (ART). These two surveys were designed to monitor the im- an NNRTI, was added. In post-PMTCT periods when these pact of HIV-1 drug resistance on the ART programme [4]. mothers needed ARVs for their own health, they were given However, a group of patients fall in a grey area not cov- the same drugs as during the prophylaxis phase- 3TC, AZT ered directly by the two surveys. This group comprised and NVP or Efavirenz (EFV-another NNRTI) but this time HIV positive women given antiretrovirals as prophylaxis as a triple therapy. Didanosine (DDI) or Abacavir (ABC)– to prevent the transmission of HIV to their babies during both NRTIs, or Tenofovir (TDF), a Nucleotide Reverse pregnancy and subsequently given treatment for their own Transcriptase Inhibitor (NtRTI) substituted AZT for some health post-partum. Bearing in mind the emergence of of the participants. HIV-positive pregnant women who drug resistance in the face of antiretroviral pressure, these reported at the Care and Support Centres and had CD4 women were given the same ARVs in the treatment phase levels below 350cells/μL were given the triple therapy with- as they were given during the prophylaxis or the phase of out a prophylactic phase [2]. preventing the transmission of the infection from the mother to the infant [2]. The effectiveness of the ARVs Sample Collection & Processing with such a background was becoming questionable in the A structured questionnaire was used to obtain basic absence of data on the resistance profiles of these women. socio-demographic and clinical data from cases and con- This study was thus designed to determine HIV-1 drug trols. Upon explaining the study and obtaining written resistance mutations present in Ghanaian women, to informed consent from the patients at the study sites, characterize any resistance mutations found according whole blood sample was taken from the antecubital vein to the class of antiretrovirals (ARVs) used during treat- of each participant into Ethylenediamine tetra-acetic ment and to provide data on the profile of HIV-1 drug acid (EDTA) treated tubes. The samples were placed in resistance present in Ghanaian women on treatment. an ice chest with frozen ice packs and transported to the Virology Department of Noguchi Memorial Institute for Methods Medical Research (NMIMR) at Legon, Accra, Ghana, Study design and sites where the plasma was separated from the whole blood This was a cross-sectional study carried out between 1st through centrifugation at 2000 g for 10 min and stored November, 2010 and 30th November, 2011 and used the at minus (−) 70 °C until analyzed. convenient sampling technique to enroll 116 HIV-1 positive Ghanaian women who accessed care and sup- HIV-1 drug-resistance genotyping port at seven National AIDS/STI Control Programme Viral RNA was extracted from 140 μL of plasma samples (NACP) centres in three regions of Ghana. using QIAamp viral RNA mini kit (Qiagen, USA). QIAGEN One-Step RT-PCR Kit was used for the amplification, Study participants according to the manufacturer’sprotocol[5]. Primers used The study involved two groups of HIV-infected mothers for the RT gene and the PR gene in the Round 1 amplifica- and a group of HIV positive pregnant women at gesta- tion were DRRT1L/DRRT4L and DRPRO5/DRPRO2L re- tional periods less than 28 weeks. One group of mothers spectively, as has previously been described [6]. The thermal (Group 1) was made up of HIV-positive mothers who cycling conditions applied were described previously [7]. had been on antiretroviral prophylaxis for prevention of Further amplification of the round 1 products was done transmission of the virus to the foetus when they were by nested PCR using AmpliTaq Gold Master Mix Kit (ABI, pregnant and had subsequently been put on full ART for USA) with primers DRRT7L/DRRT6L and DRPRO1M/ their own health needs post-partum (Prophylaxis plus DRPRO6 for RT and PR genes respectively, and the thermal ART Group). The second group (Group 2) comprised cycling conditions used were as previously described [6, 7]. HIV-positive pregnant women who had not had any The products of the RT and PR gene from the nested prior exposure to ARVs at the time of the study PCR assay were verified through the use of agarose gel (Drug-Naïve) and were pregnant at less than 28 weeks. electrophoresis and the bands in the gel were visualized A third group (Group 3) was made up of mothers who using a Gel Documentation system (GEL-LOGIC 100 had initiated ART when they were pregnant without Imaging System from Kodak) with a High Performance prophylaxis (Drug-experienced without prophylaxis) be- Ultraviolet-Transilluminator (UVP, UK). The amplicons cause their CD4 count levels were below 350 cells /μLat were purified using QIAquick PCR Purification Kit the time of ARVs initiation. (QIAGEN, USA) to obtain the DNA products needed During the study period, the PMTCT programme in for sequencing, following the manufacturer’s instruc- Ghana administered a combination of Zidovudine (AZT) tions. Cycle sequencing was performed on the purified and Lamivudine (3TC), both NRTIs, (known as Combivir) PCR products using the Big Dye Terminator Cycle Se- to the patients from 28 weeks of pregnancy as prophylaxis quencing Kit vs 3.1 from Applied Biosystems Inc. (ABI), Martin-Odoom et al. Virology Journal (2018) 15:143 Page 3 of 9 USA.